Presentation is loading. Please wait.

Presentation is loading. Please wait.

Herceptin + 17-AAG Combination BT-474 Tumors

Published byMarian Booth Modified over 9 years ago

Similar presentations

Presentation on theme: "Herceptin + 17-AAG Combination BT-474 Tumors"— Presentation transcript:

1 Herceptin + 17-AAG Combination BT-474 Tumors
Supplemental Figure 1 A. 100 200 300 400 500 600 10 20 30 40 50 Day Tumor volume (mm3) Control 17-AAG 100mg/kg 2x/wk Herceptin 20mg/kg 2x/wk Combination B. BT-474 Tumors Herceptin + 17-AAG Combination BT-474 Tumors P-AKT after Herceptin 20mg/kg x1 Time(hr) P-AKT (473) p85-PI3K

2 MEF-p95-HER2 Xenograft Tumors
Supplemental Figure 2 MEF-p95-HER2 Xenograft Tumors Time(hr) P95-HER2 P-p95-HER2

3 Supplemental Figure 3 MEF-p95-HER2 500nM SNX-2112 MCF-7-p95-HER2 500nM SNX-2112 Time(hr) p95 P-p95 P-AKT AKT P-ERK ERK

Download ppt "Herceptin + 17-AAG Combination BT-474 Tumors"

Similar presentations

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.

Supplemental figure 1 ROS production in MM cell line (KMM1) treated with bortezomib and DCA. ROS production was marginally increased by DCA in combination.
Supplemental Figure 1 A No. at risk T3 530 483 304 185 50 T2 559 545 373 228 76 T1 540 532 375 208 64.

Supplemental Figure 1 A No. at risk T T T
P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.

P-4E-BP1/4E-BP1P-p70 S6K/p70 S6K ND cleaved PARP/PARPLC3II/LC3I Supplementary Figure 1 Relative levels A BC P-Akt/Akt.
NPV-BEZ235PKI-587 GDC-0980PD0325901 Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD0325901.

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD
P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.
Figure 1. Figure : 2 BT4 before bt 0.032 0.01 1b 0.023 0.006 0.005 NR15 preT NR15 M6 BT7 preT BT7 before bt BT7 after bt BT7 postT NR19 preT NR19 M4 NR19.

Figure 1. Figure : 2 BT4 before bt b NR15 preT NR15 M6 BT7 preT BT7 before bt BT7 after bt BT7 postT NR19 preT NR19 M4 NR19.
Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.

Supplementary Figures&Legends. Figure1. Subcutaneous xenograft tumor models of the control group.
Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.

Adipose PancreasAorta MuscleHeart Liver LungKidney Testis Spleen Brian 18S p55 γ p55 α Figure S1 Tissue distribution of p55 . (A) Representative RT-PCR.
Supplemental Table 1 Source and authentication of cell lines.

Supplemental Table 1 Source and authentication of cell lines.
Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.

Con WTTM Supplementary Figure 1 Supplementary Figure 1. Tumor histopathology of the lungs. (a) Histological examination of lungs of 52-week-old K- ras.
Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX 0 0.1 1 DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05% 0 20 40 60 80 100 120 00.110.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%
A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) 0 5 10 20 Stat3:Stat3 % of Cont 100 56 43 1 Supplementary Figures Fig. S1 -

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -
Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure1 0 0.03 0.3 3 30 (µM) 120 100 80 60 40 20 0 Penetratin control % of control 0 0.03 0.3 3 30 (µM) 120 100.

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)
ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.

ПЕЧЕНЬ 9. Закладка печени в период эмбрионального развития.
The reading is 7.38 mm. The reading is 7.72 mm.

The reading is 7.38 mm. The reading is 7.72 mm.
Shimura Supplemental Figure 1

Shimura Supplemental Figure 1
Volume 20, Issue 4, Pages (October 2011)

Volume 20, Issue 4, Pages (October 2011)
Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM

Supplementary Figure 1. A B C MP-MRT-AN KP-MRT-NS KP-MRT-RY KP-MRT-YM
A B C Volume (%) Size (nm) Time (h) 3 x x x 1010

A B C Volume (%) Size (nm) Time (h) 3 x x x 1010
Relative FOXM1and Met protein levels (normalized to GAPDH)

Relative FOXM1and Met protein levels (normalized to GAPDH)

Similar presentations

Ads by Google